Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 8/20 | 0.56 |
| ▸ | LMNA | P02545 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KIF18A | Q8NI77 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | APOB | P04114 | 1/20 | 0.46 |
| ▸ | MTTP | P55157 | 1/20 | 0.46 |
| ▸ | DHX9 | Q08211 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31610032 | 0.95 | TP53 (0.63) | TP53LMNAMAPTGAATSHR | |
| SCHEMBL31610103 | 0.84 | MAPK1 (0.67) | LMNAMAPTALDH1A1MAPK1 | |
| SCHEMBL31609945 | 0.78 | ALDH1A1 (0.71) | TP53LMNAMAPTTSHRALDH1A1 | |
| SCHEMBL15848039 | 0.76 | TP53 (0.90) | TP53LMNAMAPTPOLB | |
| SCHEMBL3944742 | 0.75 | BRAF (0.75) | MAPT | |
| SCHEMBL20078764 | 0.74 | ALDH1A1 (0.58) | TP53LMNAMAPTGAAALDH1A1 | |
| SCHEMBL30926865 | 0.74 | GPR27 (0.61) | MAPTMAPK1 | |
| SCHEMBL27180015 | 0.74 | GPR27 (0.61) | MAPTMAPK1 | |
| SCHEMBL31610082 | 0.72 | HPGD (0.61) | ALDH1A1DHX9 | |
| SCHEMBL26043361 | 0.72 | HPGD (0.61) | ALDH1A1DHX9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | TP53 534/4885LMNA 1392/4885MAPT 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.